Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02960035
Other study ID # [2015]2-158
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 2014
Est. completion date October 2018

Study information

Verified date December 2019
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc fusion protein injection (Yisaipu®) in the treatment of peripheral enthesitis in active axial spondyloarthritis(SpA) patients.


Description:

Mardird sonographic enthesis index (MASEI) was one of the most wide used scoring systems for peripheral enthesitis and the only one based on OMERACT definition of enthesopathy by EULAR. The primary purpose is to assess the MASEI to discover the value of US in diagnosis and prognosis. The second prupose is to assess different maintaining treatment programme in SpA patients with improvement of MASEI. The trial will include 96 patients with stable NSAIDs therapy, and at the first stage they will receive 24-week full-dose of Yisaipu®. Then at the second stage the patients who achieve low disease activity (LDA, ASDAS<2.1) at 24th week will be randomizedly divided into three group: full-dose of Yisaipu® group, half-dose of Yisaipu® group and placebo group. And the blind stage will last for 24 weeks. Patients who complete the 48-week therapy or achieve disease-flare criteria during the blind stage would finish the study.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date October 2018
Est. primary completion date September 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Fulfill the 2009 ASAS criteria for axial spondyloarthritis(SpA), and without bilateral more than grave 2 or unilateral more than grave 3 sacroilitis on X ray plan

- Active disease phase of SpA, defined as BASDAI=4 or ASDAS=2.1

- Inadequate response to NSAID=4 week

- Application of NSAID with stable dose for no less than 2 weeks

- Stable dose of prenisone for at least four weeks at =10mg per day if used at screening, or stop use for at least 4 weeks

- Stable dose of any DMARD for at least four weeks if used at screening, or stop use for at least 4 weeks

- Stop and receiving washing out for at least 4 week if receiving Chinese traditional drug for AS, physical treatment, vaccication or IVIG

- The lab exam should achieve the criteria as below:

- Hb = 85g/L

- 3.5×109/L = WBC count = 10×109/L

- PLT = lower limit of normal range

- ALT = 2 fold of upper limit of normal range

- serum creatine = upper limit of normal range

- Negative pregnacy test for female patients. And promise to carry out contraception during the trial and 6 weeks after the trial is ended

- Sign the informed consent

Exclusion Criteria:

- Previous application of any biologic agents

- Allergic to any element of Yisaipu®

- Intolerance to NASID

- History of active tubercolosis, or radiographic evidence of present or previous history of pulmonary tubercolosis, or close contact with patients with tubercolosis, or with high risk of infection of tubercolosis such as immune suppression status, or strong positive of PPD skin test with diameter =10mm

- Presence of acute infection or acute onset of chronic infection at screen

- Invasive fungal infection or conditional infection within 6 months prior to screen

- Present or history of serious liver disease

- History of infection on artifitial joints

- Organ transplantation surgery within 6 months prior to screen

- Presence of other autoimmune diseases, including IBD, psoriasis, uveitis, SLE, multiple sclerosis, etc

- History of congestive heart failure

- History of malignancies within 5 years prior to screen, excluding complete resection of squamous cell carcinoma, or basal cell carcinoma or cervical carcinoma in situ

- AIDS or HIV infection

- History of lymphoma or lymphoproliferative disorders

- Presence of serious disorder of important organs or system

- Presence of factors which may influence the compliance

Study Design


Intervention

Drug:
50mg etanercept
Recombinant Human Tumor Necrosis Factor-a Receptor ? IgG Fc Fusion Protein Injection, 50mg per week
25mg etanercept
Recombinant Human Tumor Necrosis Factor-a Receptor ? IgG Fc Fusion Protein Injection, 25mg per week
placebo


Locations

Country Name City State
China Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The change of Mardird sonographic enthesis index (MASEI) at 24 weeks The change of Mardird sonographic enthesis index (MASEI) from week 0 to week24 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03459274 - Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology
Completed NCT06252064 - Rehabilitative Therapy and Pridinol in Patients With Lumbar Spondylarthrosis and Chronic Low Back Pain N/A
Active, not recruiting NCT02948608 - Clinical Characteristics of Importance to Outcome in Patients With Spondyloarthritis
Completed NCT03064815 - The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies N/A
Completed NCT00383617 - Referral Recommendations for Axial Spondyloarthritis N/A
Completed NCT04673825 - Monitoring Spondyloarthritis With SpA-Net N/A
Completed NCT01718951 - Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial Phase 4
Completed NCT03287596 - Cartography and Quantitative Characterization of Achilles Tendon Fibrocartilage by TE = 0ms Imaging at 3T MRI N/A
Recruiting NCT05431283 - Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy